Leiden University Scholarly Publications

Diagnostic value of a protocolized in-depth evaluation of pediatric bone marrow failure

Treatment-related risk factors for inhibitor development in non-severe hemophilia A after 50 cumulative exposure days

The factor VIII treatment history of non-severe hemophilia A

Product type and the risk of inhibitor development in nonsevere haemophilia A patients

Intensity of factor VIII treatment and the development of inhibitors in non-severe hemophilia A patients: results of the INSIGHT case-control study

Mortality caused by intracranial bleeding in non-severe hemophilia A patients

Variation in baseline factor VIII concentration in a retrospective cohort of mild/moderate hemophilia A patients carrying identical F8 mutations

Dissecting intensive treatment as risk factor for inhibitor development in haemophilia

The incidence and treatment of bleeding episodes in non-severe haemophilia A patients with inhibitors

Inhibitor development and mortality in non-severe hemophilia A

Inhibitors in nonsevere haemophilia A: outcome and eradication strategies

Inhibitors increase the burden of disease in nonsevere haemophilia A patients - treatment strategies to obtain hemostasis

Prediction of DDAVP response in 850 non-severe hemophilia A patients

Von Willebrand Factor antigen and age explain variation in baseline FVIII:C among nonsevere hemophilia A patients with the same F8 genotype (Arg593Cys and Asn618Ser)

Clinical presentation of inhibitor development in non-severe hemophilia A: half of patients have high titer inhibitors and present with bleeding complications

Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A

RISE- response to DDAVP in moderate/mild haemophilia A patients: in search for determinants

Inhibitor eradication therapy in non-severe hemophilia A

Clinical risk factors in the development of inhibitors in non-severe hemophilia A patients: the first results of the INSIGHT case-control study

Inhibitor incidence after intensive FVIII replacement for surgery in mild and moderate haemophilia A: a prospective national study in the Netherlands

Surgery and inhibitor development in hemophilia A: a systematic review

Factor VIII light chain mutations and cysteine substitutions predispose for inhibitor development in mild and moderate haemophilia A: first results from the INSIGHT study